A recent study of LGL leukemia patients treated with ruxolitinib reported that STAT3 mutations were predictive of improved event-free survival with 100% of STAT3 mutant individuals exhibiting event-free survival at 14 months compared to 40% with WT STAT3 (45). The gene discussed is STAT3; the disease is T-cell large granular lymphocyte leukemia.